SCHEDULE: Dr. Reddy's Labs Takes 9.7% Stake in Coya Therapeutics

Dr. Reddy's Laboratories, Inc. and its parent entities have disclosed a 9.7% passive beneficial ownership stake in Coya Therapeutics, Inc.

Summary

• Dr. Reddy's Laboratories, Inc., a New Jersey entity, along with its parent companies, Dr. Reddy's Laboratories SA (Switzerland) and Dr. Reddy's Laboratories Limited (India), collectively beneficially own 2,272,727 shares of Coya Therapeutics, Inc. Common Stock.
• This ownership represents 9.7% of Coya Therapeutics' outstanding Common Stock.
• The percentage is calculated based on 20,924,456 shares outstanding as of November 10, 2025, and an additional 2,522,727 shares issued and outstanding as of January 29, 2026, totaling approximately 23,447,183 shares.
• The investment is stated to be for passive purposes, not for changing or influencing control of the issuer, with the exception of activities solely related to director nominations under Rule 14a-11.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. A major pharmaceutical player taking a significant, nearly 10% stake in a therapeutics company generally signals confidence and potential strategic alignment, even if declared passive.

Positives

• A significant stake by a major pharmaceutical company like Dr. Reddy's Laboratories can be interpreted as a vote of confidence in Coya Therapeutics' potential.
• The investment by a large, established entity may provide Coya Therapeutics with increased visibility and potential future strategic opportunities.
• The ability to nominate directors under Rule 14a-11, while generally passive, could allow for strategic input or oversight from a significant industry player.

Risks

• While the investment is declared passive, the explicit mention of reserving the right for director nominations under Rule 14a-11 introduces a potential for future influence or activism, which could be perceived differently by various stakeholders.
• The calculation of the percentage of class relies on combining shares outstanding from two different dates (November 10, 2025, and January 29, 2026), which could lead to minor discrepancies if not precisely understood.

Future Outlook

The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Coya Therapeutics, Inc., other than activities solely in connection with a nomination under Rule 14a-11. This indicates a generally passive investment intent, with a reserved right to engage in proxy access for director nominations.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

StockSavvy.ai notes that Dr. Reddy's Laboratories is a significant global pharmaceutical company. Their substantial investment in Coya Therapeutics, a company likely operating in the biotechnology or therapeutics space, suggests a potential strategic interest in Coya's pipeline or technology. This move could signal validation for Coya's therapeutic approach and potentially open doors for future collaborations or partnerships within the broader pharmaceutical industry.

Corporate Governance

Stakeholder Impact

• Shareholders of Coya Therapeutics may view Dr. Reddy's Laboratories' significant stake as a positive indicator of the company's value and future prospects, potentially leading to increased investor confidence.
• Employees of Coya Therapeutics might see this as a sign of stability and potential for growth, given the backing of a large pharmaceutical entity.

Key Dates

Recommendation

A significant passive stake (9.7%) by a reputable global pharmaceutical company like Dr. Reddy's Laboratories in a therapeutics firm like Coya Therapeutics is generally a strong positive signal. It suggests a strategic interest or validation of Coya's assets, which could lead to future collaborations or acquisition interest. While the investment is declared passive, the explicit mention of proxy access rights under Rule 14a-11 indicates a potential for future influence, which could be beneficial for Coya's governance and strategic direction. This development warrants a 'buy' recommendation for investors looking for potential long-term value and strategic alignment.

Keywords

Coya Therapeutics, Dr. Reddy's Laboratories, Beneficial Ownership, Schedule 13G, Institutional Investment, Biotechnology, Pharmaceuticals, Passive Investment, Shareholder Stake